Search

Displaying results 2911 - 2920 of 5419 in total
  1. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  2. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

  3. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

  4. Drug

    OMS-103HP

    go.drugbank.com/drugs/DB05303
    Investigational

    OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.

  5. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  6. Drug

    Methyl-1-testosterone

    go.drugbank.com/drugs/DB01572
    ExperimentalIllicit

    Methyl-1-testosterone is a synthetic and orally active anabolic–androgenic steroid (AAS) which was never marketed for medical use.

  7. Drug

    Cyclopropane

    go.drugbank.com/drugs/DB13984
    Experimental

    Its use was ultimately limited because it was highly explosive.

  8. Drug

    Palmidrol

    go.drugbank.com/drugs/DB14043
    InvestigationalNutraceutical

    Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

  9. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    It was generated by HGS using the Abgenix XenoMouse technology.

  10. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.